These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 26666800

  • 1. Review: Combination umeclidinium/vilanterol improved health status more than umeclidinium in COPD.
    Stanbrook MB.
    Ann Intern Med; 2015 Dec 15; 163(12):JC10. PubMed ID: 26666800
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol.
    Malerba M, Morjaria JB, Radaeli A.
    Int J Chron Obstruct Pulmon Dis; 2014 Dec 15; 9():687-95. PubMed ID: 25061288
    [Abstract] [Full Text] [Related]

  • 4. Umeclidinium/vilanterol fixed-dose combination for COPD.
    Gras J.
    Drugs Today (Barc); 2014 Mar 15; 50(3):231-8. PubMed ID: 24696868
    [Abstract] [Full Text] [Related]

  • 5. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
    Rodrigo GJ, Neffen H.
    Chest; 2015 Aug 15; 148(2):397-407. PubMed ID: 25798635
    [Abstract] [Full Text] [Related]

  • 6. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.
    Donohue JF, Singh D, Munzu C, Kilbride S, Church A.
    Respir Med; 2016 Mar 15; 112():65-74. PubMed ID: 26797016
    [Abstract] [Full Text] [Related]

  • 7. Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.
    Kelly E.
    Expert Rev Clin Pharmacol; 2014 Jul 15; 7(4):403-13. PubMed ID: 24909949
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol.
    Cazzola M, Segreti A, Matera MG.
    Drug Des Devel Ther; 2013 Jul 15; 7():1201-8. PubMed ID: 24143077
    [Abstract] [Full Text] [Related]

  • 10. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
    Kardos P, Worsley S, Singh D, Román-Rodríguez M, Newby DE, Müllerová H.
    Int J Chron Obstruct Pulmon Dis; 2016 Jul 15; 11():2885-2895. PubMed ID: 27932872
    [Abstract] [Full Text] [Related]

  • 11. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study.
    Mehta R, Kelleher D, Preece A, Hughes S, Crater G.
    Int J Chron Obstruct Pulmon Dis; 2013 Jul 15; 8():159-67. PubMed ID: 23569370
    [Abstract] [Full Text] [Related]

  • 12. Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial.
    Kerwin EM, Boucot IH, Vogelmeier CF, Maltais F, Naya IP, Tombs L, Jones PW, Lipson DA, Keeley T, Bjermer L.
    Ther Adv Respir Dis; 2020 Jul 15; 14():1753466620926949. PubMed ID: 32462979
    [No Abstract] [Full Text] [Related]

  • 13. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
    Feldman G, Walker RR, Brooks J, Mehta R, Crater G.
    Pulm Pharmacol Ther; 2012 Dec 15; 25(6):465-71. PubMed ID: 22955035
    [Abstract] [Full Text] [Related]

  • 14. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease.
    Blair HA, Deeks ED.
    Drugs; 2015 Jan 15; 75(1):61-74. PubMed ID: 25398674
    [Abstract] [Full Text] [Related]

  • 15. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
    Feldman GJ, Edin A.
    Ther Adv Respir Dis; 2013 Dec 15; 7(6):311-9. PubMed ID: 24004659
    [Abstract] [Full Text] [Related]

  • 16. Umeclidinium-vilanterol inhaler approved for COPD.
    Traynor K.
    Am J Health Syst Pharm; 2014 Feb 01; 71(3):174. PubMed ID: 24429003
    [No Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease.
    Goyal N, Beerahee M, Kalberg C, Church A, Kilbride S, Mehta R.
    Clin Pharmacokinet; 2014 Jul 01; 53(7):637-48. PubMed ID: 24756395
    [Abstract] [Full Text] [Related]

  • 18. Umeclidinium bromide/vilanterol trifenatate, perampanel, and eslicarbazepine acetate.
    Hussar DA, Dharsi N.
    J Am Pharm Assoc (2003); 2014 Jul 01; 54(4):450-2, 454-5. PubMed ID: 25063267
    [No Abstract] [Full Text] [Related]

  • 19. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
    Kerwin E, Ferguson GT, Sanjar S, Goodin T, Yadao A, Fogel R, Maitra S, Sen B, Ayers T, Banerji D.
    Lung; 2017 Dec 01; 195(6):739-747. PubMed ID: 28993871
    [Abstract] [Full Text] [Related]

  • 20. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
    Lee L, Kerwin E, Collison K, Nelsen L, Wu W, Yang S, Pascoe S.
    Respir Med; 2017 Oct 01; 131():148-157. PubMed ID: 28947022
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.